DOCSLIB.ORG

140+ Investors, Pharma and Commercial Leaders You Need to Know

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
140+ Investors, Pharma and Commercial Leaders You Need to Know 140+ investors, pharma and commercial leaders you need to know Who are some of the leading investors, pharma and commercial leaders most active this side of the Atlantic? Published by COMPANIES SUMMARISED INTRODUCTION What follows in this ebook is a summary of 140+ of the life science industry’s most notable and active venture capital, corporate venture, strategic investors, PE/crossovers, pharma companies and commercial leaders. The geography of this list is primarily UK and EU, but with several key US firms also listed. They represent $bns of combined assets under management across therapeutics, diagnostics and medtech. If you don’t already have a relationship with them, these are firms you should want to get to know. The selection represents a current snapshot of the investment, pharma firms and commercial leaders currently signed up to the 5th Annual LSX World Congress (formerly Biotech/Medtech and Money World Congress conference), taking place from 5-6 February in London 2019. In this ebook we provide a snapshot of the firms themselves, plus some key aggregated statistics of their investment and partnering preferences. COMPANIES SUMMARISED 4BIO Capital F-Prime Capital New Rhein Healthcare Investors Abingworth Forbion Capital Partners Norgine Ventures Accelerace Future Care Capital Novartis Accelmed GIMV Novo Nordisk Advent Life Sciences GL Capital Novo Seeds Aglaia Biomedical Ventures Gilde Healthcare Novo Ventures Albion Capital Global Core Medical NVM Private Equity Alsa Holdings GSK o2h Andera Partners Hadean Ventures OrbiMed Apollo Ventures HBM Partners Oxford Technology Management Areterial Capital Management Healthcap Oxon Arix Bioscience Hermes Partners Panacea Venture Arterial Capital Management High-Tech Gründerfonds Panakes Partners Asabys Ignite Capital Partners Peppermint Venture Partners Astellas Imec.Xpand Philips Health Technology Ventures AstraZeneca Industrifonden Polar Capital Bayer InHealth Ventures Questra BioCity Inkef Capital Redalpine Venture Partners BioGeneration Ventures Innogest RMI Partners Bioscience Managers Inventages Roche BioSeed Capital IP Group Rosetta Capital BlueOcean Ventures IPF Partners Ruffena Capital BNP Paribas Asset Management Ipsen Sanara Ventures Boehringer Ingelheim Jolt Capital Sanofi Bond Asian Ventures JPIF SBI JI Innovation Fund Boston Scientific Ventures Julz Co Seroba Life Sciences Breed Reply Juvenescence Seventure Bridge Valley Ventures Kissei SHS Capital Business Integration Partners Kreos Capital Siemens Healthineers Cambridge Innovation Capital Kurma Partners Simcere Pharmaceutical Group Capricorn Venture Partners LifeArc Sixth Element Capital Cascara Ventures Bvba Livanova Smith & Nephew Catapult Ventures Livzon Pharmaceutical Group Sofinnova Partners CeiRox Life Sciences Longwall Ventures SOSV Clubb Capital LSP BioVentures Spark Impact DiaMedCare M Ventures SR-One DeBere Capital Partners Medicxi Swedbank Robur Deepbridge Capital MedImmune Syncona DN Capital Medtronic Takeda Downing LLP Mercia Technologies Teva Earlybird Venture Capital Merck & Co Truffle Capital Eli Lilly MSD TusPark UK EMD Serono MTIP TVM Capital Life Science EMV Capital MVM Partners UCB Venture Enterprise Ireland NCL Technology Ventures UCL Technology Fund Epidarex Capital NeoMed UKI2S Esperante NetScientific UVM Health Network Ventures Excite Capital Partners Newable Private Investing Ventac Partners FirstMinute Capital Newstar Ventures Xeraya Capital FMC (First Momentum Ventures) New Mosaic 4BIO Capital United Kingdom 4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech - biologics, gene and cell therapy and bioinformatics. Abingworth United Kingdom For almost 30 years, Abingworth has been working alongside entrepreneurs to develop their ideas into products that have a dramatic impact on health. With a broad transatlantic approach to backing innovation, we invest in drugs, devices and diagnostics from seed-stage start-ups to publicly traded companies. By harnessing advances in life sciences, we have built a succession of companies and helped to create one of the world’s most vibrant and important industries. Abingworth has raised 11 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Clinical Co-Development Fund and Abingworth Bioventures VI, raised $105 million and £225 million ($375 million) respectively and are actively investing. Abingworth has $1.1bn under management and has invested in over 140 life science companies. Accelerace Denmark We were founded back in 2008 pioneering the accelerator space in Europe with a rebellious spirit and lofty objective: to take great technologies of tomorrow and even greater teams under our wing to make them fly. Today, this is still our mission. Building on our knowledge, we believe that talent is the key to where it all begins: Talented people with an entrepreneurial drive to challenge the status quo can be found at home, working in their sheds, labs or on their laptops. However, not all of them are visible at a glance. Our ability to spot these people and nurture their ideas and talent is the most meaningful task you can take on and we’re dedicated to that. Accelmed United Kingdom Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and invests in small and mid- cap private and public companies. With its proven track record and large team of accomplished investment professionals, Accelmed’s vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel. Advent Life Sciences United Kingdom Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced team with a long- standing track record of entrepreneurial and investment success through turning break-through science into approved medicines or medical products. We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities med tech, enabling technologies and vaccines. As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well connected team to support each investment. We work in close alignment with our management teams, and partner with them to realise their vision - achieving superior financial returns by bringing innovation to patients. Aglaia Biomedical Ventures The Netherlands Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. We invest in novel tools and technologies as well as components of contemporary drug development. Albion Capital United Kingdom Albion Capital is a leading independent investment manager with a long-term record of backing change and growth. Combining a thematic, returns-driven investment approach with specialist expertise, we target those sectors where we see opportunities for the creation of long-term value. We are generalist investors, with areas of particular focus including healthcare and technology. Albion’s focus is on longevity as partners in order to maximise the returns for our investors and the management teams for whom we support. Within healthcare and life sciences we invest in areas including digital health, diagnostics and imaging. We also invest in commercialising IP from University College London via the UCL Technology Fund, including all aspects of life sciences from therapeutics to devices. Alsa Holdings United Kingdom ALSA Holdings is a private investment vehicle with considerable pharma, biotech and CRO strength, particularly in clinical stage development. Agnostic in terms of therapeutic area, we are principally focused on companies looking to progress to proof of concept as the next step. We are committed to working closely with management to accelerate development programs utilizing the full breadth of collective scientific and industry operational expertise to help bring new products to market. Andera Partners France Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas: Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. Apollo Ventures Germany Apollo Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer’s, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in
Load more

Recommended publications
  • Diversity in UK Venture Capital 2019 2
    A report by Diversity VC Sponsored by Silicon Valley Bank Published July 2019 Diversity in UK Venture Capital 2019 2 With thanks to our Research Team Executive Team Diversity Research Team 2019 Diversity VC Team Travis Winstanley Diane Albouy David Kelnar Shriya Anand Research Lead, Co-founder, Diversity VC Balderton Capital MMC Ventures Bain & Company Catalis Group Meriwether Beckwith Dan Mackie Seb Butt Lillian Li Oxford Capital Craft.co Co-founder, Diversity VC Kirsty MacDonald Eight Roads Ventures Victoria Bernath JamJar Investments Juliet Bailin University of York Mosaic Ventures Francesca Warner, CEO Patricia Nicola Co-founder, Diversity VC James Downing Seedrs Ben Goldsmith Diversity VC Silicon Valley Bank Goldsmith Communications Shane Porter Bain & Company Sarah Millar Blake Falk Citylight Capital Bain & Company Magda Posluszny Speed Invest Esther Delignant Rodriguez Christina Franzeskides Oxford Capital Entrepreneur First (LD12) Lucy Rands ETF Partners Tong Gu Michael Tefula Downing Ventures Accelerated Digital Ventures Abhi Setia London School of Economics Belinda Gurung Farooq Abbasi Constanoa Ventures JamJar Investments Shrenik Sanghrajka Bain & Company Harry Hamer London Venture Partners Imran Tehal DN Capital Julie Kainz Salesforce Ventures Ella Wales Bonner JamJar Investments Full list of contributors is available in the Appendix. Diversity in UK Venture Capital 2019 3 Contents Foreword 5 Introduction 6 Key Findings 10 Gender 12 Education 17 Career 21 Ethnicity 24 Discussion 26 Conclusion 36 About Diversity VC 40 Appendix 42 References 42 Our Contributors 42 Our Sponsor 46 Our Partners and Collaborators 47 Our Methodology 48 Firms in our analysis 52 Diversity in UK Venture Capital 2019 4 Launch of Women in UK Venture Capital (2017) Source: Diversity VC Diversity in UK Venture Capital 2019 Introduction Foreword 5 A warm welcome to ‘Diversity in UK Venture Capital 2019’.
    [Show full text]
  • Equity Crowdfunding: All Regulated but Not Equal
    DePaul Business and Commercial Law Journal Volume 13 Issue 3 Spring 2015 Article 2 Equity Crowdfunding: All Regulated but Not Equal Garry A. Gabison Follow this and additional works at: https://via.library.depaul.edu/bclj Recommended Citation Garry A. Gabison, Equity Crowdfunding: All Regulated but Not Equal, 13 DePaul Bus. & Com. L.J. 359 (2015) Available at: https://via.library.depaul.edu/bclj/vol13/iss3/2 This Article is brought to you for free and open access by the College of Law at Via Sapientiae. It has been accepted for inclusion in DePaul Business and Commercial Law Journal by an authorized editor of Via Sapientiae. For more information, please contact [email protected]. Equity Crowdfunding: All Regulated but Not Equal Garry A. Gabison* This Article describes how different countries have approached eq- uity crowdfunding. It focuses on countries or regulatory authorities that either expressed their awareness of the phenomenon but decided to adopt a holding pattern (monitoring and investigating) or new laws and regulations. Countries like Australia have opted to reaffirm how their current set of regulations applies to crowdfunding whereas others like the United States, Italy, the United Kingdom, and France have elected to create new exemptions in an effort to facilitate equity crowdfunding. This Article compares how each country decided to regulate the different participantsin the crowdfunding process. While the results of these various efforts are still mostly unseen, this Article takes an early look at the regulatory impact using one U.K. based platform as an example of how regulations can boost investment. CONTENTS I. INTRODUCTION ...........................................
    [Show full text]
  • Stepstone Atlantic Fund, L.P
    StepStone Atlantic Fund, L.P. Private Equity and Infrastructure Quarterly Monitoring Report For the period ending December 31, 2020 Report Prepared For: Important Information This document is meant only to provide a broad overview for discussion purposes. All information provided here is subject to change. This document is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, or as an offer to provide advisory or other services by StepStone Group LP, StepStone Group Real Assets LP, StepStone Group Real Estate LP, StepStone Conversus LLC, Swiss Capital Alternative Investments AG and StepStone Group Europe Alternative Investments Limited or their subsidiaries or affiliates (collectively, “StepStone”) in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. The information contained in this document should not be construed as financial or investment advice on any subject matter. StepStone expressly disclaims all liability in respect to actions taken based on any or all of the information in this document. This document is confidential and solely for the use of StepStone and the existing and potential clients of StepStone to whom it has been delivered, where permitted. By accepting delivery of this presentation, each recipient undertakes not to reproduce or distribute this presentation in whole or in part, nor to disclose any of its contents (except to its professional advisors), without the prior written consent of StepStone. While some information used in the presentation has been obtained from various published and unpublished sources considered to be reliable, StepStone does not guarantee its accuracy or completeness and accepts no liability for any direct or consequential losses arising from its use.
    [Show full text]
  • The Acceleration Point: Why Now Is the Time for European Venture Capital Invest Europe the Acceleration Point: Why Now Is the Time for European Venture Capital
    EUROPEAN VENTURE CAPITAL The Acceleration Point: Why Now is the Time for European Venture Capital Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital C Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital Contents What’s in this report 01 Foreword Section One: Section Two: Why Now is the Time Why Europe? Europe’s Innovation for European Venture Capital Why Now? Pages 04-15 Economy Pages 16-22 By Nenad Marovac Invest Europe Vice-Chair 1 2 Page 02 Page 04 Page 17 A strong economy committed European tech cities to growth Page 18 Page 05 Benelux European VC is experienced Page 19 Page 07 France, Spain & Switzerland Proven ability to create global leaders To find out more about Invest Europe please visit: Page 20 Page 09 Germany Increased exit options www.investeurope.eu Page 21 Page 11 UK & Ireland Outsized returns in a low-yield environment Page 22 Scandinavia Page 13 Robust fundraising Page 15 Page 23 Europe’s hottest sectors In conclusion For PDF download to your computer: Page 24 Please visit our website at www.investeurope.eu if you would like to download this report as References and data methodology a standalone PDF. Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital Foreword Foreword by Nenad Marovac 02 Why now is the time for European venture capital The European venture capital (VC) industry has reached an acceleration point. Europe’s prospering economies, the unprecedented rise of the European tech industry and the region’s experienced fund managers make it the right time to invest in European venture capital.
    [Show full text]
  • NOAH Berlin 2018
    Table of Contents Program 6 Venture Capital 10 Growth 107 Buyout 124 Debt 137 Trading Comparables 143 2 Table of Contents Venture Capital Buyout 3TS Capital Partners 11 Frog Capital 50 SevenVentures 90 Apax 125 83North 12 General Catalyst 51 Speedinvest 91 Ardian 126 Accel Partners 13 German Media Pool 52 SpeedUp Venture Capital 92 Bain Capital 127 Acton Capital Partners 14 German Startup Group 53 Group Capvis Equity Partners 128 Astutia Ventures 15 Global Founders Capital 54 STS Ventures 93 EQT Partners 129 Atlantic Labs 16 GPS Ventures 55 Swisscom Ventures 94 FSN Capital Partners 130 AVentures Capital 17 GR Capital 56 TA Ventures 95 GENUI 131 AXA Venture Partners 18 Griffon Capital 57 Target Partners 96 KKR 132 b10 I Venture Capital 19 High-Tech Gruenderfonds 58 Tengelmann Ventures 97 Macquarie Capital 133 BackBone Ventures 20 HV Holtzbrinck Ventures 59 Unternehmertum Venture 98 Maryland 134 Balderton Capital 21 IBB 60 Capital Partners Oakley Capital 135 Berlin Technologie Holding 22 Beteiligungsgesellschaft Vealerian Capital Partners 99 Permira 136 idinvest Partners 61 Ventech 100 Bessemer Venture 23 Partners InMotion Ventures 62 Via ID 101 BCG Digital Ventures 24 Innogy Ventures 63 Vito Ventures 102 BFB Brandenburg Kapital 25 Inovo.vc 64 Vorwerk Ventures 103 Intel Capital 65 W Ventures 104 BMW iVentures 26 Iris Capital 66 WestTech Ventures 105 Boerste Stuttgart - Digital 27 Kizoo Technology Capital 67 XAnge 106 Ventures Debt btov Partners 28 Kreos Capital 68 LeadX Capital Partners 69 Buildit Accelerator 29 Lakestar 70 CapHorn Invest
    [Show full text]
  • Ff&P Venture Funds Pcc Limited
    FF&P VENTURE FUNDS PCC LIMITED Interim Report and Unaudited Consolidated Financial Statements For the six month period ended 30 September 2014 FF&P VENTURE FUNDS PCC LIMITED Financial Statements for the period ended 30 September 2014 Contents Page Directors and Administration 2 Statement of Directors' Responsibilities 3 Investment Adviser's Report 4 - 9 Investment Portfolio Statement - (Cell I) 10 Investment Portfolio Statement - (Cell II) 11 - 12 Investment Portfolio Statement - (Cell III) 13 Investment Portfolio Statement - (Cell IV) 14 Investment Portfolio Statement - (Cell V) 15 Investment Portfolio Statement - (Cell VI) 16 Investment Portfolio Statement - (Cell VII) 17 Investment Portfolio Statement - (Cell VIII) 18 Investment Portfolio Statement - FF&P Venture Funds Subsidiary Limited 19 Consolidated Statement of Total Return 20 - 21 Consolidated Statement of Movements in Equity Shareholders' Funds 22 - 23 Consolidated Balance Sheet 24 - 25 Consolidated Cash Flow Statement 26 Notes to the Financial Statements 27 - 43 FF&P VENTURE FUNDS PCC LIMITED Page 2 Directors and Administration Directors: Richard Crowder (Chairman)* Rupert Evans Lewis Grant* All of the current directors are non-executive. With the exception of Richard Crowder, all directors are members of the Audit Committee. * Independent directors Registered Office: 11 New Street St Peter Port Guernsey, GY1 2PF Manager: FF&P Asset Management (Guernsey) Limited 11 New Street St Peter Port Guernsey, GY1 2PF Investment Adviser: FF&P Asset Management Limited 15 Suffolk Street
    [Show full text]
  • Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 1/22/2018 – 1/26/2018 (Transactions in Excess of $20 Million)
    Private Capital Group Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 1/22/2018 – 1/26/2018 (Transactions in excess of $20 million) Trends & Commentary . This week, 10 U.S. private placement deals between $20 million and $50 million closed, accounting for $279 million in total proceeds, compared to last week’s 11 U.S. deals leading to $372 million in total proceeds. This week also had 7 U.S. deals between $50 million and $100 million yielding $475 million, compared to last week’s 3 deals resulting in $168 million in total proceeds. A growing number of deals with companies from China have been blocked by the U.S. government, including Ant Financial’s bid for MoneyGram and more recently, HNA Group’s bids for SkyBridge Capital and Glencore. Primary Data, a data virtualization startup, is shutting down after raising $40 million in Series C funding in 2017, and nearly $90 million in total funding to date from Accel Partners, Battery Ventures and Lightspeed Venture Partners, among others. Despite having industry experts such as Steve Wozniak and Fusion.io’s co-founders David Flynn and Rick White, the Company is being shut down reportedly due to heavy operating losses. Sapphire Ventures has promoted Rajeev Dham, Kevin Diestel and Anders Ranum to Partner. The Company also promoted Winter Mead to Principal. Snowflake, a cloud-based data storage platform, has become the first unicorn of 2018 after being valued at $1.5 billion in its Series E round from ICONIQ Capital and Altimeter Capital. SoundHound, a developer of sound recognition and voice search technologies, is following suit with its Series D1 round projected to close at the end of January.
    [Show full text]
  • NOAH Berlin 2018
    Table of Contents Program 7 Venture Capital 10 Growth 126 Buyout 150 Debt 165 2 Table of Contents Venture Capital Growth 3TS Capital Partners 11 ECONA 50 Project A 92 Accel Partners 128 83North 12 Eight Roads 51 PropTech1 Ventures 93 Activant Capital 129 ACT Ventures 13 Endeit Capital 52 ProSiebenSat.1 Accelerator 94 BlackFin Capital Partners 130 Acton Capital Partners 14 FJ Labs 53 QD Ventures 95 Burda Principal Astutia Ventures 15 Fluxunit - OSRAM Ventures 54 Redalpine 96 Investments 131 Atlantic Labs 16 Frog Capital 55 Redline Capital 97 CapitalD 132 Aventures 17 General Catalyst 56 Red-stars.com data AG 98 Egmont 133 Axa Venture Partners 18 German Media Pool 57 Redstone 99 EMK Capital 134 b10 19 German Startups Group 58 RTA Ventures 100 General Atlantic 135 BackBone Ventures 20 Global Founders Capital 59 RTP Global 101 GPI Capital 136 Balderton Capital 21 Global Ventures 60 Samos Investments 102 Great Hill Partners 137 BCG Digital Ventures 22 GPS Ventures 61 Schibsted Growth 103 Horizon Capital 138 Beringea 23 GR Capital 62 Seventure Partners 104 HPE Growth Capital 139 Berlin Technologie Holding 24 Griffon Capital 63 SevenVentures 105 Insight Venture Partners 140 Bessemer Venture Partners 25 Hammer Team 64 SmartFin 106 LetterOne 141 BFB Brandenburg Kapital 26 Hearst Ventures 65 SpeedInvest 107 NGP Capital 142 BMW iVentures 27 High-Tech Gruenderfonds 66 SpeedUp Venture Capital NuCom Group 143 Boerse Stuttgart Digital Holtzbrinck Ventures 67 Group 108 Scottish Equity Partners 144 Ventures 28 i5invest 68 STIHL Digital 109 Stripes Group
    [Show full text]
  • Windeln.De Closes €45 Million Investment Round Led by Goldman Sachs, Deutsche Bank, DN Capital, MCI Management and 360 Capital Partners
    windeln.de closes €45 million investment round led by Goldman Sachs, Deutsche Bank, DN Capital, MCI Management and 360 Capital Partners 20.01.2015 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. windeln.de, the German online retailer and flash sales platform for baby and children products (the “Company”), today announced that a consortium led by Goldman Sachs and Deutsche Bank invested €45 million in the Company. The investment comes to support the Company’s plans for strategic expansions and is intended to finance: The expansion of the Company’s product portfolio The Company’s geographic roll-out Potential acquisitions “2014 has been a great year for windeln.de with gross revenue of €130 million”, said Alexander Brand, Managing Director and Co-Founder of windeln.de. “After a year in which we were able to almost double our gross revenues, we are even more delighted to welcome Goldman Sachs as a new shareholder. We consider this as a clear vote of confidence in our vision and strategic plans by a world-class investor. As we continue to grow, windeln.de will benefit from Goldman Sachs’ financing expertise and knowledge of key geographies and end markets.” Martin Hintze, Managing Director and Co-head of Corporate Equity Investing in Europe of Goldman Sachs Merchant Banking Division, said: “windeln.de is an emerging European leader in the pure-play online retail of baby products. We believe that consumers will continue to move away from offline to online and we share the management team’s vision to grow the business in the German-speaking region and beyond.
    [Show full text]
  • DENVER CAPITAL MATRIX Funding Sources for Entrepreneurs and Small Business
    DENVER CAPITAL MATRIX Funding sources for entrepreneurs and small business Sixth Edition Introduction Denver Economic Development & Opportunity (DEDO) Definitions is pleased to release this sixth edition of the Denver Venture Capital – Venture capital is capital provided by investors to Capital Matrix. small businesses and start-up firms that demonstrate possible high- growth opportunities. Venture capital investments have a potential for This publication is designed as a tool to assist business considerable loss or profit and are generally designated for new and owners and entrepreneurs with discovering the myriad speculative enterprises that seek to generate a return through a of capital sources in and around the Mile High City. potential initial public offering or sale of the company. The Denver Capital Matrix provides a comprehensive Angel Investor – An angel investor is a high net worth individual active in directory of financing sources, from traditional bank venture financing, typically participating at an early stage of growth. lending, to venture capital firms, private equity firms, angel Private Equity – Private equity is an individual or consortium of investors investors, mezzanine sources and more. and funds that make investments directly into private companies or Small businesses provide the greatest opportunity for job initiate buyouts of public companies. Private equity is ownership in private companies that is not listed or traded on public exchanges. This is creation today. Yet, a lack of needed financing often prevents considered an illiquid and long-term investment. businesses from implementing expansion plans and adding payroll. Through this updated resource, DEDO strives to help Mezzanine Financing – Mezzanine financing is a hybrid of debt and connect businesses to equity financing that is typically used to finance the expansion of start- up and expansion capital so that they can thrive in existing companies.
    [Show full text]
  • Equity Signatures As at December 2020
    Equity Signatures as at December 2020 Deal Team Commitment EFSI EFSI Name Resource location (EURm) SMEW SMEWII Private Equity 1.289,9 ABAC SUSTAINABLE VALUE II FCR EFSI - SMEW, OWN FUNDS Spain 40,0 Yes No Abenex VI OWN FUNDS, RCR France 20,0 Yes No Aksia Capital V OWN FUNDS, RCR Italy 30,0 No No Alcedo V AMUF - GC, OWN FUNDS, RCR Italy 60,0 No No Argos Wityu Mid-Market VIII OWN FUNDS, RCR France 60,0 No No ASEF SCSp EFSI - SMEW, OWN FUNDS, NPI SM - HBOR Croatia 25,0 Yes No Avallon MBO Fund III SCA SICAV-RAIF AMUF - GC, EFSI - SMEW, OWN FUNDS Poland 30,0 Yes No Axcel VI K/S 2 AMUF - GC Denmark 20,0 Yes No Beyond Capital Partners Fund II GmbH & Co. KG COSME-EFG, OWN FUNDS, RCR Germany 30,0 Yes No BlackPeak Southeast Europe Growth Equity Fund SCSp COSME-EFG, OWN FUNDS, JER-009 BULGARIA Bulgaria 32,0 No No Blue Sea Capital Fund II SCSp EFSI - SMEW, OWN FUNDS Croatia 25,0 Yes No Bluegem III SCSp OWN FUNDS, RCR United Kingdom 30,0 No No CMF-Cipio Partners German CMF Luxembourg 10,3 No No Crest II FCR OWN FUNDS, NPI SM - IFD ( Portugal Growth), RCR Portugal 20,0 No No Development Capital Fund II EFSI - SMEW, OWN FUNDS Ireland 30,0 Yes No eEquity IV AB ESCALAR Sweden 37,1 Yes No Ergon Capital Partners V SCSp AMUF - GC, OWN FUNDS, RCR Belgium 44,0 No No Espiga Equity Fund II COSME-EFG, OWN FUNDS, RCR Spain 30,0 No No Evoco TSE III OWN FUNDS, RCR Switzerland 40,0 Yes No FSN Capital VI L.P.
    [Show full text]
  • July 2020 NAXS AB
    NAXS AB July 2020 www.naxs.se. Grev Turegatan 10, 1tr, SE-114 46 Stockholm, Sweden. Phone: +46 (0) 8 611 33 25 NAXS Permanent capital focusing on the Nordic market • NAXS is a company listed on NASDAQ Stockholm and investing primarily in Buyout funds Commitment Fund Size private equity funds with a Nordic focus. NAXS may also make direct Apax Europe VII EUR 15m EUR 11bn investments or co-investments alongside private equity or other alternative FSN Capital III EUR 10m EUR 375m assets funds. In addition, NAXS may, to a limited extent, make other types Herkules Private Equity III NOK 40m NOK 6bn of investments. Intera Fund I EUR 7m EUR 125m Intera Fund II EUR 7,25m EUR 200m • Listed in 2007, the company currently offers an attractive exposure to the JAB Consumer Fund – GCB II USD 5bn private equity segment: JAB Consumer Fund – GCB III • 11 private equity funds from 8 managers Nordic Capital Fund VII EUR 20m EUR 4.3bn • 39 underlying portfolio companies (remaining after 94 exits) Nordic Capital CV1 EUR 4m EUR 2.5bn Valedo Fund II SEK 65m SEK 2bn • 6 vintage years (2007, 2008, 2011, 2017, 2018 and 2020) and exposure to large, mid and small cap segments • NAXS also offers an exposure to 2 listed companies: Special situations fund Commitment Fund Size • Scout Gaming Group, a provider of Daily Fantasy Sports listed on Mimir Invest AB SEK 50m < SEK 500m NASDAQ First North • Awilco Drilling, a drilling operator listed on the Oslo exchange • In addition, NAXS holds a senior secured bond issued in 2018 by Jacktel Direct investments Size of initial investment Scout Gaming Group SEK 9.5m AS, a wholly-owned subsidiary of Master Marine AS.
    [Show full text]